Your browser doesn't support javascript.
loading
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.
Dittrich, Christian; Fridrik, Michael A; Koenigsberg, Robert; Lee, Chooi; Goeldner, Rainer-Georg; Hilbert, James; Greil, Richard.
Afiliação
  • Dittrich C; Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology and Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna), Third Medical Department, Center for Oncology and Hematology, Kaiser-Franz-Josef-Spital, Vienna, Austria, christian.dittrich@wienkav.at.
Invest New Drugs ; 33(2): 409-22, 2015 Apr.
Article em En | MEDLINE | ID: mdl-25529193
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Serina-Treonina Quinases / Inibidores de Proteínas Quinases / Aurora Quinase B / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Serina-Treonina Quinases / Inibidores de Proteínas Quinases / Aurora Quinase B / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Ano de publicação: 2015 Tipo de documento: Article